They found that the subjects treated with GLP-1RAs, compared with those undergoing DPP-4 inhibitors, did not have a lower risk of developing liver cirrhosis, while patients treated with SGLT-2 inhibitors had a lower risk of liver cirrhosis compared to those undergoing DPP-4 inhibitors [175]. This evidence concerns the gene SLC5A2 and cirrhosis of liver.